Pune: Hospitals who treat covid-19 patients who are seriously ill face the lack of toclillizumab – anti-rheumatic drugs found effective in counteracting the abnormal immune storm – abnormal immune response.
Shyam Pratapwar, Assistant Commissioner (Medicine), Food and Drug Administration (FDA), Pune, said, “There is a lack of Toctizumab for a week now.
Unlike remdesivir, Todilizumab is still distributed to treat hospitals only opposing the requirements through the Collectorate District because of that It is imported medicine and the supply is always erratic.
We did our best to refill stock in Pune.
“The patient referred to the hospital in Pune in a fairly large number of other places has caused the Tocilizumab crisis.
At present, more than 90% of Covid-19 patients who are recognized in the city are called rural parts of Pune and neighboring districts.
Expert Infectious Diseases of Noble Hospital Ameet Dravid said, “We get some severe Covid patients from coexistent districts such as Ahmednagar and Solapur.
In addition, young covid patients who are seriously ill are being referred to us from hospitals in Baramati and other Talukas In the countryside of Pune.
Most of these serious patients need tokilizumab but there are shortcomings.
“Doctors use other drugs remembering the lack of totilizumab.
“There are anti-cancer drugs, anti-ulcerative colitis, and immunosuppressant drugs that we can use but research has not proven it is very useful in Covid.” “The supply of toilizumab is always erratic.
We have used drugs subcutaneously in certain patients,” said Deenanath Mangeshkar, the PARIXHIT PRYAG infectious disease.
Pune Hospitals wrestle with Totilizumab’s shortcomings
